Skip to content

Dynamic changes of skeletal muscle parameters during chemotherapy in the background of cancer patients with nutritional active intervention

Dynamic changes of skeletal muscle parameters during chemotherapy in the background of cancer patients with nutritional active intervention

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056758
Enrollment
Unknown
Registered
2022-02-13
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Group A:Active nutrition intervention

Sponsors

Ordos Central Hospital, Inner mongolia
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Aged >= 18 years,and pathologically diagnosed malignant tumor; 2.KPS score=70; 3.Before chemotherapy, liver and kidney function, blood routine, electrocardiogram are normal.Blood tests must meet the requirements of white blood cells > 3.5 * 10^9, neutrophils > 1.5 *10^9, platelets > 85 *10^9, alkaline phosphatase less than 2.5 times of normal value,alanine aminotransferase andaspartate aminotransferase=2.5 times of normal value, bilirubin 1.5 times of normal value, and creatinine 1.5 times of normal value; 4.No other liver,kidney and blood system diseases. 5.No contraindication of chemotherapy. 6.No intervention (such as surgery) to change body composition before CT and chemotherapy 7.Accept BIA, CT and follow-up. 8.Obtain the patient's informed consent and sign the consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with contraindications to chemotherapy. 2.Patients are bedridden and cannot cooperate with nutritional assessment. 3.Patients with other severe consumptive diseases. 4.Patients who had a long history of hormone use. 5.Patients with HIV, active hepatitis, kidney disease and other diseases that affect drug excretion or drug metabolism 6.Patients who are prophylactic application of long-acting leucovorin before chemotherapy. 7.Patients who terminate anti-tumor treatment voluntarily or fail to perform physical analysis or follow-up of side effects according to the rules.

Design outcomes

Primary

MeasureTime frame
muscle area of lumbar vertebra;

Secondary

MeasureTime frame
bioelectrical impedance;NRS2002 scale;PG-SGA scale;

Countries

China

Contacts

Public ContactLi Quanfu
1729259137@qq.com0477-8363279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026